Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2023-04-07 Proxy Solicitation & In…
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the 2023 Annual Meeting of Aytu BioPharma, Inc. It includes voting items such as election of directors, approval of an equity incentive plan, advisory vote on executive compensation, and ratification of the independent auditor. The content is focused on soliciting shareholder votes and providing information about the meeting proposals, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). The document length is 3663 characters, which is typical for proxy materials. Therefore, the correct classification is PSI with high confidence.
2023-04-07 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-07 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or corporate changes that shareholders should know about. The content describes amendments to loan and security agreements and financial obligations, which are typical subjects of a Capital/Financing Update. The document is not a full financial report like an Annual Report (10-K) or Quarterly Report (IR), nor is it a simple announcement of a report publication. It contains substantive information about financing amendments and obligations. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6301 characters) supports it being a substantive filing rather than a brief announcement or certification.
2023-03-27 English
10-Q
Interim / Quarterly Report Q2 2023
2023-02-21 English
10-Q/A
Interim / Quarterly Report Q1 2023
2023-02-21 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results and a business update for the fiscal quarter ended December 31, 2022. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3611 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, if a document is short and announces or furnishes a report (like a press release of earnings), it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR) because the actual financial data is in the press release exhibit, not the 8-K text itself. Therefore, the best classification is Regulatory Filings (RNS).
2023-02-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.